Wyeth Articles
Wyeth's Lybrel approved by FDA
28 May 2007
Wyeth wins Philadelphia HRT trial
21 May 2007
Wyeth submits OIC drug to EMEA
21 May 2007
Wyeth's Puerto Rico plant gets FDA OK
14 May 2007
Japan stock market week to May 7, 2007
14 May 2007
Meda buys 10 Wyeth drugs
7 May 2007
FDA issues "approvable" letter for bazedoxifene
30 April 2007
UK study links HRT to ovarian cancer
30 April 2007
Wyeth's 1st-qtr income up 12% to $1.25B
30 April 2007
Surprise rise in German drug investment
23 April 2007
Wyeth's Prevenar EU license extended
23 April 2007
FDA extends review on Wyeth's first-in-class mTOR inhibitor, Torisel, in advanced renal cell carcinoma
16 April 2007
Stock Commentary - New York week to April 9
16 April 2007
Bifeprunox shows good weight and lipid profile
9 April 2007
Zeltia's Yondelis enters Phase III
9 April 2007
Progenics files new OIC treatment with FDA
9 April 2007
Wyeth Japan names Susumu Kurata as president
2 April 2007
FDA approves ammendments to Wyeth's BeneFIX
2 April 2007
Controversy over US flu vacc stock destruction
2 April 2007
Controversy over US flu vacc stock destruction
2 April 2007
Altana's EBITDA up 50%, after drug division sale
26 March 2007
Wyeth ends SCOLR license deal
19 March 2007
Prevnar gets positive opinion from CHMP
12 March 2007
Wyeth updates on Guayama inspection
12 March 2007
Wyeth appoints Geno Germano as president
5 March 2007
Biovitrum's FY 2006 net profit plummets 47.4%
5 March 2007
Headlines 25 years ago this week....
26 February 2007
80% of pediatricians favor childhood vaccs, says Wyeth study
26 February 2007
Final US OK for Mylan's propranolol ER
26 February 2007
US FDA warns about misrepresented drugs bought over the Internet
26 February 2007
FDA warns of risks with Merck & Co's RotaTeq
19 February 2007
Mexico's pharma agenda: protected data, patents
19 February 2007
New Rapamune dosing guide OKed by FDA
12 February 2007
Wyeth enters three major collaborations
12 February 2007
Wyeth hormone law suit dismissed
12 February 2007
Wyeth promotes Bernard Poussot
5 February 2007
Wyeth's income up 17%, but shares fall 2.5%
5 February 2007
Wyeth named "best CNS pipeline"
5 February 2007
Par Pharma's generic Inderal OKed in USA
5 February 2007
Wyeth gets tentative US approval for Pristiq
29 January 2007
Hungary issues list of non-pharmacy OTCs
29 January 2007
Stock Commentary - New York week to Jan 15, 2007
22 January 2007
Wyeth and Solvay announce new accord
22 January 2007
Catalyst signs $100M Alterase R&D deal with Wyeth
15 January 2007
Patent expiry will "constrain" antibacterial market
15 January 2007
TMRC sets first round of research project funding
15 January 2007
Pharmacopeia signs $189M JAK3 Wyeth deal
15 January 2007
RA biological competitors spent $195M on promotion
8 January 2007
Wyeth/Progenics initiate Ph III trial of POI treatment
22 December 2006
Wyeth vacc could save one child per hour in Latin America
22 December 2006
FDA priority review for Wyeth's Torisel
22 December 2006
"Brain drain" reversal boosts India's drug R&D
22 December 2006
Patent expiries will stem growth of antidepressants market
18 December 2006
MRSA increases for sixth year running in EU hospitals
18 December 2006
Wyeth updates on UK roll out of Enbrel PFS
18 December 2006
Wyeth applauds GAVI decision on pneumococcal vaccine
11 December 2006
Wyeth warns shareholders on mini-tender offer
11 December 2006
Pfizer increases 2006 earnings forecast
11 December 2006
Neurogen acquires global Aplindore rights form Wyeth
4 December 2006
Wyeth names Robert Landry as treasurer
27 November 2006
Intercell's 9 month losses deepen 21.8%
27 November 2006
Ablynx and Wyeth sign Nanobody R&D deal
13 November 2006
MacuSight initiates 30-patient sirolimus trial
6 November 2006
US FDA issues overdose warning on Effexor
6 November 2006
Wyeth reports strong Ph II data on TSECs
6 November 2006
Affymetrix and Wyeth extend GeneChip deal
30 October 2006
ViroPharma and Wyeth start Ph II trial of HCV antiviral
30 October 2006
Progenics receives $5M milestone from Wyeth
30 October 2006
Wyeth's income climbs 33% to $1.16B in 3rd-qtr, on continued success of Enbrel and Prevnar
30 October 2006
Solvay and Wyeth file bifeprunox with FDA
23 October 2006
Wyeth unveils seven late-stage drugs for 11 indications at its annual R&D presentation
16 October 2006
Enbrel demonstrates long-term safety profile
16 October 2006
Biotica grants Wyeth $195M rapamycin license
16 October 2006
Wyeth raises full-year guidance
9 October 2006
UPDATE: ICAAC 2006 sees strong data on next-gen antibiotics: Tygacil, ceftaroline, cethromycin
9 October 2006
Wyeth's Tygacil comparable to J&J's Levaquin
9 October 2006
Enbrel launched in prefilled syringes UK
9 October 2006
Methylnaltrexone enters trials for POI
2 October 2006
Jury finds in Wyeth favor in HRT case
25 September 2006
Blockbuster status forecast for Enbrel by 2010
18 September 2006
Big Pharma needs to catch up with specialty detailing
18 September 2006
Ligand sells oncology line to Eisai and Avinza to King for total $518M
18 September 2006
Sweden's Biovitrum launches IPO
11 September 2006
Zealand Pharma raises cash for R&D
11 September 2006
FDA extends its review of Wyeth's desvenlafaxine
4 September 2006
Methylnaltrexone enters Ph II OIC study
4 September 2006
Wyeth submits 2 NDAs for menopause drugs
4 September 2006
FDA cancels Wyeth's MDD drug PDAC talks
4 September 2006
Wyeth looks to Synmetrics to enhance its target profiling
28 August 2006
FDA approves generic venlafaxine
14 August 2006
Wyeth's revenues hit $5.2B for 1st-half 2006
31 July 2006
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
